Full-Time

Director/Sr. Director

Business Development & Operations

Confirmed live in the last 24 hours

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology

Compensation Overview

$215k - $295kAnnually

+ Performance Bonus + Equity

Senior, Expert

Palo Alto, CA, USA

Hybrid work environment.

Category
Business Development
Business & Strategy
Required Skills
Data Analysis
Requirements
  • PhD or MD from top-tier academic institutions or scientific undergrad with commensurate work experience
  • Strategic planning, operating, and program management experience working with a close-knit team at a biotech startup or top-tier pharma
  • Management Consulting or Banking experience from top tier firm
Responsibilities
  • Learn quickly the scientific, operational, and external facing facets of Gondola programs
  • Set, prioritize, and manage milestones & deliverables for team members in one or more of the Gondola programs
  • Coordinate team meetings and delegate to technical experts in one or more of the Gondola Programs
  • Interpret, collate, and communicate key data findings in a succinct manner to senior management
  • Identify problems, locate the resources, and find data-driven solutions independent of supervision

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific diseases while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create therapies that address the genetic roots of diseases, potentially leading to significant improvements in patient health. With a diverse pipeline of over 15 drug programs targeting 20 genetic diseases, BridgeBio aims to bring treatments to market more quickly than traditional biopharma processes. The company promotes a culture of independent thinking and transparency, encouraging rigorous testing of innovative ideas to drive data-driven decision-making.

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

20%

1 year growth

52%

2 year growth

101%
Simplify Jobs

Simplify's Take

What believers are saying

  • Increased investment in genetic disease R&D aligns with BridgeBio's focus.
  • Decentralized clinical trials benefit BridgeBio's subsidiary model for faster drug development.
  • Expansion of personalized medicine boosts demand for BridgeBio's targeted therapies.

What critics are saying

  • Alnylam's Amvuttra poses competitive pressure on BridgeBio's Attruby.
  • KRAS inhibitors face significant scientific hurdles, impacting BridgeBio's oncology efforts.
  • Decentralized model may challenge cohesive strategic direction across drug programs.

What makes BridgeBio unique

  • BridgeBio employs a unique decentralized subsidiary model for efficient drug development.
  • Focus on genetic diseases with well-understood causes sets BridgeBio apart in biopharma.
  • BridgeBio leverages genome sequencing and molecular biology for targeted therapy development.

Help us improve and share your feedback! Did you find this helpful?